Abstract
Glucagon-like peptide-1 (GLP-1) is involved in satiety control and glucose homeostasis. Besides, GLP-1 has cardiovascular effects. In experimental models, GLP-1 increases cardiac output and exerts a direct vasodilatory effect. In animals with dilated cardiomyopathy GLP-1 improves left ventricular performance. Human data demonstrated that GLP-1 reduces arterial blood pressure, improves endothelial function in individuals with diabetes and left ventricular function in patients with heart failure. Administration of GLP-1 increases ejection fraction in acute myocardial infraction and reduces ischemia-reperfusion myocardial injury. Although more research is needed, these data suggest that GLP-1 may be used with promising results in patients with heart failure, acute myocardial infarction and revascularization procedures in addition to the standard therapy.
Keywords: Arterial blood pressure, cardiovascular, endothelium, glucagon-like peptide 1, heart failure, left ventricular function, type 2 diabetes mellitus, GLP-1, T2DM, cell proliferation, insulin resistant and hyperlipidemic, glomerulosclerosis, angiotensin II, Bilateral vagotomy, hyperglycemia, dilated cardiomyopathy, norepinephrine, cediranib, thrombolysis, angioplasty, low-flow ischaemia, flow mediated vasodilatation, LVEF, acetylcholine, acute occlusive ischemia
Mini-Reviews in Medicinal Chemistry
Title: Cardiovascular Effects of Glucagon-Like Peptide 1
Volume: 11 Issue: 1
Author(s): A. Papazafiropoulou, S. I. Pappas, D. Papadogiannis and N. Tentolouris
Affiliation:
Keywords: Arterial blood pressure, cardiovascular, endothelium, glucagon-like peptide 1, heart failure, left ventricular function, type 2 diabetes mellitus, GLP-1, T2DM, cell proliferation, insulin resistant and hyperlipidemic, glomerulosclerosis, angiotensin II, Bilateral vagotomy, hyperglycemia, dilated cardiomyopathy, norepinephrine, cediranib, thrombolysis, angioplasty, low-flow ischaemia, flow mediated vasodilatation, LVEF, acetylcholine, acute occlusive ischemia
Abstract: Glucagon-like peptide-1 (GLP-1) is involved in satiety control and glucose homeostasis. Besides, GLP-1 has cardiovascular effects. In experimental models, GLP-1 increases cardiac output and exerts a direct vasodilatory effect. In animals with dilated cardiomyopathy GLP-1 improves left ventricular performance. Human data demonstrated that GLP-1 reduces arterial blood pressure, improves endothelial function in individuals with diabetes and left ventricular function in patients with heart failure. Administration of GLP-1 increases ejection fraction in acute myocardial infraction and reduces ischemia-reperfusion myocardial injury. Although more research is needed, these data suggest that GLP-1 may be used with promising results in patients with heart failure, acute myocardial infarction and revascularization procedures in addition to the standard therapy.
Export Options
About this article
Cite this article as:
Papazafiropoulou A., I. Pappas S., Papadogiannis D. and Tentolouris N., Cardiovascular Effects of Glucagon-Like Peptide 1, Mini-Reviews in Medicinal Chemistry 2011; 11 (1) . https://dx.doi.org/10.2174/138955711793564033
DOI https://dx.doi.org/10.2174/138955711793564033 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiovascular Disease Burden and Risk Factors Before and After Kidney Transplant
Cardiovascular & Hematological Disorders-Drug Targets Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design Editorial [Hot Topic: Cardiovascular and Hematological Agents (Executive Editor: Johann Auer)]
Current Pharmaceutical Design Resveratrol and Cardiac Fibrosis Prevention and Treatment
Current Pharmaceutical Biotechnology HER2 in the Era of Molecular Medicine: A Review
Current Cancer Therapy Reviews Proinflammatory Gene Polymorphisms and Ischemic Stroke
Current Pharmaceutical Design Disease Progression in Children with Vertically-Acquired HIV Infection in Sub-Saharan Africa: Reviewing the Need for HIV Treatment
Current HIV Research Pharmacology of TRP Channels in the Vasculature
Current Vascular Pharmacology Cardio-Vascular Risks Associated with Clozapine Treatment
Current Psychiatry Reviews Emerging Role for Antioxidant Therapy in Protection Against Diabetic Cardiac Complications: Experimental and Clinical Evidence for Utilization of Classic and New Antioxidants
Current Cardiology Reviews Current Evidence from Phase III Clinical Trials of Selenium Supplementation in Critically Ill Patients: Why Should We Bother?
Mini-Reviews in Medicinal Chemistry Separating Fact from Fiction: Assessing the Potential of Modified Adenovirus Vectors for Use in Human Gene Therapy
Current Gene Therapy Antioxidant Properties of Melatonin and its Potential Action in Diseases
Current Topics in Medicinal Chemistry Enteral and Parenteral Nutrition Therapy for Crohns Disease
Current Pharmaceutical Design Comparison of High-Sensitive CRP, RDW, PLR and NLR between Patients with Chronic Obstructive Pulmonary Disease and Chronic Heart Failure
Current Respiratory Medicine Reviews Stress, Cardiovascular Diseases and Surgery-Induced Angiogenesis
Current Angiogenesis (Discontinued) Diabetic Cardiomyopathy: Clinical and Metabolic Approach
Current Vascular Pharmacology Pharmacological Regulators of Intracellular Calcium Release Channels
Current Pharmaceutical Design Dystroglycan, A Multifunctional Adaptor Protein for Signal Transduction and A Potential Therapeutic Target
Current Signal Transduction Therapy Diabetes Mellitus and Vascular Endothelial Dysfunction: Current Perspectives
Current Vascular Pharmacology